logo-loader
/**/ h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h4{margin-top:2.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri Light","sans-serif";color:#2F5496;font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .av{size:612.0pt 792.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.av{}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:15.0pt;line-height:normal}p.cc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.cd{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.ce{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.cf{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.cg{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bw{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.ch{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; margin: 0cm; margin-bottom: .0001pt; text-align: center} span.bu{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.ci{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:12.1pt;margin-right:0cm;margin-bottom: 12.1pt;margin-left:0cm;text-align:justify;line-height:normal}table.cj{width:490.5pt;margin-left:-5.4pt;border-collapse:collapse}td.bq{width:225.9pt; padding:0cm 5.4pt 0cm 5.4pt}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;font-weight: bold; line-height: normal; margin-bottom: 0cm}td.bo{width:243.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;margin-bottom:0cm;margin-bottom:.0001pt; line-height:normal}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;line-height: normal; margin-bottom: 0cm; text-align: right}td.bm{width:249.95pt; padding:0cm 5.4pt 0cm 5.4pt}td.bl{width:218.95pt;padding:0cm 5.4pt 0cm 5.4pt} td.bk{width:237.65pt; padding:0cm 5.4pt 0cm 5.4pt}td.bj{width:231.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.bi{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.bf{width:281.25pt; padding:0cm 5.4pt 0cm 5.4pt}span.bh{color:#0070C0;text-decoration: none}span.bg{color:#0070C0}td.be{border:none}p.cn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;background:white}span.bc{color:#212121}p.co{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; margin-left: 0cm; margin-right: -22.3pt; margin-top: 0cm; text-align: justify} span.ba{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}p.cp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-22.3pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify}span.cq{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.ax{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.aw{margin-top:0cm;margin-right:-22.3pt;margin-bottom:0cm;margin-left: 0cm;margin-bottom:.0001pt;text-align:justify} /**/
RNS Number : 3151K
Collagen Solutions PLC
28 August 2019
 

28 August 2019

Collagen Solutions plc

("Collagen Solutions" or the "Company")

 

AGM Statement

Delivering on our growth strategy

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, will hold its Annual General Meeting at 11am today at their offices at 3 Robroyston Oval, Nova Business Park, Glasgow, G33 1AP. At the meeting, Jamal Rushdy, CEO of Collagen Solutions will make the following statement:

"Building on a successful fundraise in June, and momentum from our most recent financial year, we remain positive about our outlook and on track with our key initiatives for the year. Our core business is seeing continued growth as expected to support our goal of further improvement on overall financial performance in line with market expectations. We are also progressing with infrastructure projects to increase our capacity for contract manufacturing while we also expand our tissue supply. We are engaged in active dialogue with our notified body regarding our application for CE marking ChondroMimetic®, consistent with our plan to resolve open questions in time to gain approval in the financial year, while the response time or additional questions by the notified body still cannot be guaranteed. Finally, our global R&D team is executing on several key customer product development projects supporting a strong pipeline of contract manufacturing over the next several years."

Collagen Solutions Plc

 

Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO

 

 

 

Cenkos Securities Plc (Nominated Adviser and Broker)

 

Giles Balleny

Tel: 0207 397 8900

Stephen Keys

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected] 

Anna Dunphy

Mob: 07876 741 001

 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

 

For more information go to: www.collagensolutions.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
AGMEASPXADDNEFF

Quick facts: Collagen Solutions PLC

Price: 3.45

Market: LSE
Market Cap: £15.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Collagen Solutions released financial number showing more...

Collagen Solutions (LON: COS) CEO Jamal Rushdy joined Steve Darling from Proactive to discuss the company releasing their financial numbers that show impressive double-digit sales growth.  Rushdy talks about the numbers and also their tissue division that continues to be a revenue driver.

4 weeks, 2 days ago